Life Sciences
Top stories summarized by our editors
10/20/2017

GlaxoSmithKline and Plasticell have partnered to manufacture hematopoietic cells from induced pluripotent stem cells using the Plasticell's stem cell screening technology called Combinatorial Cell Culture, or CombiCult, based on molecular combinations to be provided by GSK. No financial details of the partnership were disclosed.

10/20/2017

Although the number of orphan drugs has increased considerably since 2012, these drugs comprise only 8% of US drug costs, according to a QuintilesIMS Institute report.

Full Story:
BioPharma Dive
10/20/2017

A round of Series B financing has brought in $75 million for Forty Seven. The company has ongoing Phase I and Phase Ib/II studies of Hu5F9-G4 as a monotherapy and in combination use with Rituxan/MabThera or Vidaza for the treatment of solid tumors and hematological malignancies.

Full Story:
BioCentury
10/20/2017

A sensitization workshop of Nigerian seed companies was initiated by the National Agriculture Seed Council in preparation for the commercialization of biotech Bacillus thuringiensis cowpea and cotton next year. The workshop aims to educate the seed companies on their anticipated roles in the distribution of biotech seeds.

Full Story:
Leadership Nigeria
10/20/2017

A letter was sent by 22 members of the House Biofuels Caucus to the Environmental Protection Agency asking the EPA not to reduce the biodiesel blending requirements in 2018 and 2019. The letter also urged the agency to not allow ethanol exports to qualify for renewable fuel credits.

Full Story:
Reuters
10/20/2017

As many as 20% of pharmaceutical brands are transitioning their investment from digital media to digital point-of-care marketing through health care providers, a ZS Associates study found. A decrease in television viewing and tracking problems online have contributed to the shift, said Health Media Marketing SVP Alicesa Vongluekiat.

More Summaries:
digital media, ZS Associates
10/20/2017

Pfizer is working with Boston Globe's BG BrandLab on a "Dear Scientist" video campaign meant to remind viewers that scientists are not just lab rats -- rather, they devote countless years to projects meant to make a difference in the lives of real people, whose letters scientists read on screen. Pfizer is BrandLab's first pharma client, but BG BrandLab chief Doug Most hopes to add others from Boston's thriving biotech and pharma industry.

Full Story:
FiercePharma
More Summaries:
Pfizer, Doug Most, Boston Globe, BrandLab
10/20/2017

A round of seed financing pulled in $3.1 million for San Clemente, Calif.-based Spinal Singularity. The money will be used for clinical validation of the company's Connected Catheter, which is designed to last 29 days, reducing urinary tract infections and replacing disposable intermittent catheters in men with chronic lower urinary tract dysfunction.

Full Story:
MassDevice (Boston)
10/20/2017

An agreement has been reached by Johnson & Johnson's German device unit, Johnson & Johnson GmbH, to buy Surgical Process Institute, a German software firm that specializes in surgical workflow standardization and digitization in the surgical theater. The acquisition, for which terms were not disclosed, is expected to be completed this quarter.

10/20/2017

A round of financing brought in about $2.1 million for Irish medtech company AventaMed, a spin-out from the Cork Institute of Technology's Medic research center, that makes the Solo Tympanostomy Tube Device for simplifying insertion of plastic ear tubes in pediatric patients with ear infections and hearing loss. The proceeds will be used to help the company secure approval from the FDA and enter the US market.